AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Teva Pharmaceutical Industries Ltd.

Director's Dealing Mar 6, 2024

7082_rns_2024-03-05_204003be-a0da-4312-9a77-a846df545976.pdf

Director's Dealing

Open in Viewer

Opens in native device viewer

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response ... 0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person
Grant Angus
2. Issuer Name and Ticker or Trading Symbol
Teva Pharmaceutical Industries Limited TEVA
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director
10% Owner
Officer (give title below)
Other (specify below)
EVP, Business Development
(Last)
(Middle)
(First)
C/O Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.,
3. Date of Earliest Transaction (Month/Day/Year)
03/04/2024
(Street)
Tel Aviv, L3 6944020
(City)
(State)
(Zip)
4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security 12. Transaction 2A. Deemed 3. Transaction 4. Securities Acquired 5. Amount of Securities Beneficially 7. Nature
(Instr. 3) Date Execution Date, if Code (A) or Disposed of (D) Owned Following Reported Ownership of Indirect
(Month/Day/Year) any (Instr. 8) (Instr. 3, 4 and 5) Transaction(s) Form: Beneficial
(Month/Day/Year) (Instr. 3 and 4) Direct (D) Ownership
or Indirect (Instr. 4)
(A) or (1)
Code Amount (D) Price (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)

1. Title of 3. Transaction 3A. Deemed 5. Number 6. Date Exercisable 7. Title and Amount 8. Price of 9. Number of 10 11. Nature
Derivative Conversion Date Execution Date, if Transaction of Derivative and Expiration Date of Underlying Derivative Derivative Ownership of Indirect
Security or Exercise (Month/Day/Year) any Code Securities (Month/Day/Year) Securities Security Securities Form of Beneficial
(Instr. 3) Price of (Month/Day/Year) (Instr. 8) Acquired (Instr. 3 and 4) (Instr. 5) Beneficially Derivative Ownership
Derivative (A) or Owned Security: (Instr. 4)
Security Disposed of Following Direct (D)
(D)
(Instr. 3, 4,
and 5)
Reported or Indirect
Transaction(s) (1)
(Instr. 4) (Instr. 4)
Amount
or
Date Expiration Title Number
Exercisable Date of
Code (A) (D) Shares
Restricted Ordinary
Share (1) 03/04/2024 A 52,083 (2) (2) Shares 52,083 \$ 0 52,083 D
Units (3)

Explanation of Responses:

    1. Each restricted share unitingent right to reevie, at settlement, one ordinary share or, at the option of the Human Resources and Committer, the cash vale of one ordinary share.
    1. Restincted share were granted on March 4, 2024, with 13,120 vesting on each of March 4, 2027, and 13,028 vesing on March 4, 2028
    1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Signatures

/s/ Dov Bergwerk as attorney-in-fact for Angus Grant 03/05/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly.

  • * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
  • ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 18tf(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of in this form are not required to respond unless the form displays a currently valid OMB Number.

Talk to a Data Expert

Have a question? We'll get back to you promptly.